InVivoMAb anti-human EGFR
The 528 monoclonal antibody reacts with an epitope on the extracellular domain of human EGFR (epidermal growth factor receptor) also known as ErbB-1. EGFR is a 170 kDa cell-surface receptor and belongs to the ErbB family of receptors. EGFR signaling is activated upon binding one of its ligands including epidermal growth factor (EGF), transforming growth factor α (TGF α), Amphiregulin, and heparin binding-EGF (HB-EGF). Upon activation, EGFR transitions from an inactive monomeric form to an active homodimer. This initiates several downstream signal transduction cascades including the MAPK, Akt and JNK pathways, leading to DNA synthesis and cell proliferation. EGFR overexpression or constitutive activation are associated with many cancers. For this reason, anti-EGFR monoclonal antibody mediated immunotherapies are currently being explored as cancer treatments. The 528 antibody has been reported to block EGF binding to its receptor and inhibit A431 tumor formation in nude mice.
|Recomended Isotype Control(s)||InVivoMAb mouse IgG2a isotype control, unknown specificity|
|Recommended InVivoPure Dilution Buffer||InVivoPure pH 7.0 Dilution Buffer|
Purified EGFR from A431 cells
0.2 μM filtered
Purified from tissue culture supernatant in an animal free facility
Undiluted at 4°C in the dark